{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:26:30Z","timestamp":1784129190300,"version":"3.55.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.diabet.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T07:08:28Z","timestamp":1556262508000},"page":"406-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy"],"prefix":"10.1016","volume":"46","author":[{"given":"M.","family":"Bastin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mosbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boudifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Villemain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hartemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andreelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2019.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2019.04.005_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM200002033420501","article-title":"A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group","volume":"342","author":"Imagawa","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.04.005_bib0015","doi-asserted-by":"crossref","first-page":"a007732","DOI":"10.1101\/cshperspect.a007732","article-title":"Genetics of type 1 diabetes","volume":"2","author":"Noble","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.diabet.2019.04.005_bib0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","article-title":"Genetics of the HLA region in the prediction of type 1 diabetes","volume":"11","author":"Noble","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabet.2019.04.005_bib0025","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","author":"-Marchand","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2019.04.005_bib0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CJI.0000000000000218","article-title":"Diabetes and blood glucose disorders under anti-PD1","volume":"41","author":"Magis","year":"2018","journal-title":"J Immunother"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363619300655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363619300655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:56:53Z","timestamp":1761130613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363619300655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1262363619300655"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2019.04.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}